Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022

/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...

Related Keywords

United States ,China ,Florida ,Japan ,Orange County Convention Center ,Canada ,Orlando ,Japanese ,American ,Fosun Pharma ,Prnewswire Ardelyx Inc ,American Society Of Nephrology ,Kyowa Kirin Co Ltd ,Ardelyx Inc ,Nasdaq ,American Society ,Kidney Week ,Kyowa Kirin ,Poster Presentations ,Predictive Value ,Early Response ,Patients Receiving Maintenance ,Exhibit Hall ,Serum Phosphorus ,With Tenapanor ,Chronic Kidney Disease ,Dialysis With Severe ,Reduces Interdialytic Weight Gain ,Post Hoc Analysis ,Kirin Poster Presentations ,Japanese Hemodialysis Patients ,Randomized Phase ,Tenapanor Added ,Phosphate Binders ,Existing Phosphate Binders ,Exhibitor Spotlight ,Phosphorus Management Puzzle ,New Pieces ,Physician Perspective ,Saturday November ,Geoff Block ,Knight Therapeutics ,Ardelyx ,